TAPISTRY: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You Platform Study
Condition: Solid Tumors
Sponsor: Hoffmann-La Roche
Full Title
BO41932: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Eligibility/Info
Patients must have received at least 1 line of therapy in the advanced/metastatic setting and fit one of the following cohorts:
Cohort A: Entrectinib in ROS1-fusion positive solid tumors (excludes non-small cell lung cancer)
Cohort B: Entrectinib in NTRK1/2/3-fusion positive solid tumors
Cohort C: Alectinib in ALK-fusion positive solid tumors (excludes non-small cell lung cancer)
Cohort K: Pralserinib in RET-fusion positive solid tumors
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.